The role of single fraction Gamma Knife radiosurgery for intraventricular central neurocytomas and the utility of F-18 fluroethyltyrosine: two case reports.
Central neurocytoma
F-18 FET
Gamma Knife
Radiosurgery
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
28 Nov 2022
28 Nov 2022
Historique:
received:
30
12
2021
accepted:
01
11
2022
entrez:
27
11
2022
pubmed:
28
11
2022
medline:
30
11
2022
Statut:
epublish
Résumé
Primary treatment of central neurocytomas is surgical resection. Gamma Knife surgery is considered a valuable therapeutic option in case of residual (after subtotal resection) or recurrent central neurocytomas. Here, we focused on the role of F-18 fluroethyltyrosine as a marker to document tumor progression after initial resection, in the context of an atypical central neurocytoma. We also describe MIB-1's role in evaluating therapeutic decision-making. Two patients with central neurocytomas were treated by Gamma Knife surgery in our center. The first case (31-year-old Caucasian male) had atypical central neurocytoma. Four and a half years after surgical resection, magnetic resonance imaging and F-18 fluroethyltyrosine documented clear progression of residual central neurocytoma, further treated by Gamma Knife surgery (18 Gy at 50%, target volume 1.4 cc, and prescription isodose volume 1.8 cc). The initial post-Gamma Knife surgery clinical course was uneventful, with progressive volumetric reduction of residual tumor up to 4.5 years, when out-of-field recurrence was suspected and confirmed by local F-18 fluroethyltyrosine hyperactivity. Second single-fraction Gamma Knife surgery was performed (18 Gy at 50%, target volume 0.49 cc, prescription isodose volume 0.72 cc). The second (32-year-old Caucasian female) had previous subtotal resection and typical central neurocytoma. Seven years later, she had residual tumor progression. Single-fraction Gamma Knife surgery was performed (16 Gy at 50% isodose line, target volume 1.7 cc, and prescription isodose volume 2.5 cc). Last follow-up showed tumor volume reduction. Follow-up magnetic resonance imaging showed important volumetric reduction of both treated lesions. In atypical central neurocytomas, F-18 fluroethyltyrosine could be used as postoperative examination to detect small tumor remnants, follow-up evaluation following the Gamma Knife surgery or, in select cases, following surgical resection. The role of MIB-1 is important in therapeutic decision-making, as tumors with MIB-1 exceeding 2% are characterized by more aggressive clinical course. Single-fraction Gamma Knife surgery remains a valuable therapeutic option for postoperative residual atypical central neurocytomas and central neurocytoma recurrences.
Sections du résumé
BACKGROUND
BACKGROUND
Primary treatment of central neurocytomas is surgical resection. Gamma Knife surgery is considered a valuable therapeutic option in case of residual (after subtotal resection) or recurrent central neurocytomas. Here, we focused on the role of F-18 fluroethyltyrosine as a marker to document tumor progression after initial resection, in the context of an atypical central neurocytoma. We also describe MIB-1's role in evaluating therapeutic decision-making.
CASE PRESENTATION
METHODS
Two patients with central neurocytomas were treated by Gamma Knife surgery in our center. The first case (31-year-old Caucasian male) had atypical central neurocytoma. Four and a half years after surgical resection, magnetic resonance imaging and F-18 fluroethyltyrosine documented clear progression of residual central neurocytoma, further treated by Gamma Knife surgery (18 Gy at 50%, target volume 1.4 cc, and prescription isodose volume 1.8 cc). The initial post-Gamma Knife surgery clinical course was uneventful, with progressive volumetric reduction of residual tumor up to 4.5 years, when out-of-field recurrence was suspected and confirmed by local F-18 fluroethyltyrosine hyperactivity. Second single-fraction Gamma Knife surgery was performed (18 Gy at 50%, target volume 0.49 cc, prescription isodose volume 0.72 cc). The second (32-year-old Caucasian female) had previous subtotal resection and typical central neurocytoma. Seven years later, she had residual tumor progression. Single-fraction Gamma Knife surgery was performed (16 Gy at 50% isodose line, target volume 1.7 cc, and prescription isodose volume 2.5 cc). Last follow-up showed tumor volume reduction. Follow-up magnetic resonance imaging showed important volumetric reduction of both treated lesions.
CONCLUSIONS
CONCLUSIONS
In atypical central neurocytomas, F-18 fluroethyltyrosine could be used as postoperative examination to detect small tumor remnants, follow-up evaluation following the Gamma Knife surgery or, in select cases, following surgical resection. The role of MIB-1 is important in therapeutic decision-making, as tumors with MIB-1 exceeding 2% are characterized by more aggressive clinical course. Single-fraction Gamma Knife surgery remains a valuable therapeutic option for postoperative residual atypical central neurocytomas and central neurocytoma recurrences.
Identifiants
pubmed: 36437467
doi: 10.1186/s13256-022-03665-4
pii: 10.1186/s13256-022-03665-4
pmc: PMC9703805
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
441Subventions
Organisme : Université de Lausanne
ID : Jeune Chercheur en Recherche Clinique
Informations de copyright
© 2022. The Author(s).
Références
Acta Neuropathol. 1982;56(2):151-6
pubmed: 7064664
J Neurosurg. 2020 Apr 03;134(3):1122-1131
pubmed: 32244212
J Neurooncol. 2011 Dec;105(3):647-57
pubmed: 21732073
Prog Neurol Surg. 2019;34:232-237
pubmed: 31096256
Cancer. 1997 Feb 15;79(4):790-5
pubmed: 9024717
Neurosurg Clin N Am. 2003 Oct;14(4):483-508
pubmed: 15024797
Neurology. 2004 Mar 23;62(6):987-9
pubmed: 15037708
Brain Pathol. 1993 Jul;3(3):297-306
pubmed: 8293189
Acta Neurochir (Wien). 2016 Nov;158(11):2235-2236
pubmed: 27663880
J Clin Neurosci. 2013 Jan;20(1):89-93
pubmed: 23137668
Neurosurg Clin N Am. 2015 Jan;26(1):37-44
pubmed: 25432182
Eur Radiol. 2010 Oct;20(10):2496-502
pubmed: 20521054
J Neurosurg. 2012 Dec;117 Suppl:96-101
pubmed: 23205795
J Neurooncol. 2003 Feb;61(3):255-9
pubmed: 12675319
Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1145-54
pubmed: 17187939
Cancer. 2004 Feb 15;100(4):814-7
pubmed: 14770439
World Neurosurg. 2016 Jun;90:300-305
pubmed: 26987638
J Neurol Neurosurg Psychiatry. 2001 Apr;70(4):489-93
pubmed: 11254772
Cancer. 2005 Jul 1;104(1):135-42
pubmed: 15880432
Neuro Oncol. 2016 Mar;18(3):426-34
pubmed: 26243791
Neurology. 2002 Oct 22;59(8):1268-70
pubmed: 12391364
Cancer. 1995 Oct 1;76(7):1224-32
pubmed: 8630902
Ann Nucl Med. 2001 Apr;15(2):161-5
pubmed: 11448077
J Neurooncol. 2006 Sep;79(2):211-6
pubmed: 16552620
Cancer. 1999 Apr 1;85(7):1606-10
pubmed: 10193953
Am J Surg Pathol. 2001 Oct;25(10):1252-60
pubmed: 11688459
J Neuropathol Exp Neurol. 1997 May;56(5):551-6
pubmed: 9143268
Acta Radiol. 2015 Jan;56(1):114-20
pubmed: 24477268
Neurosurg Clin N Am. 2015 Jan;26(1):57-66
pubmed: 25432184
Cancer. 2007 Nov 15;110(10):2276-84
pubmed: 17926332